Thank you for your comments. We acknowledge and concur with your opinion regarding the assertion that high-dose interferon is associated with a significant survival benefit. Our guideline has been corrected to reflect this, and the latest iteration states that “Our review of the available literature identified no systemic adjuvant therapy that confers a significant survival benefit in patients with high-risk resected primary melanoma. However high-dose interferon treatment should be considered in such patients as such therapy is associated with significant improvement in disease-free survival and reduction in 2-year mortality.”
. 2006 Apr;13(2):77.
Reply from Dr. Shailendra Verma
Shail Verma
1
Shail Verma, MD
1Melanoma Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative, Program in Evidence-based Care, McMaster University, 3rd Floor, 1280 Main Street West, Hamilton, Ontario L8S 4L8
Co-Chair
Find articles by Shail Verma
1Melanoma Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative, Program in Evidence-based Care, McMaster University, 3rd Floor, 1280 Main Street West, Hamilton, Ontario L8S 4L8
Roles
Shail Verma: MD, Co-Chair
2006 Multimed Inc.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC1891176